Oral Anticoagulation

Among adults with nonvalvular atrial fibrillation, direct oral anticoagulant initiation was associated with lower risk for renal failure or progression of chronic kidney disease compared with vitamin K antagonist initiation, data show.

Direct oral anticoagulation in patients not previously indicated for it who underwent transcatheter aortic valve replacement was associated with increased mortality compared with antiplatelet therapy, researchers reported.

Direct oral anticoagulants significantly reduced risk for recurrence of cancer-associated venous thromboembolism compared with dalteparin among patients with cancer, according to study results published in Mayo Clinic Proceedings.

Direct oral anticoagulants (DOACs) or warfarin in patients with central venous thrombosis.

For prevention of venous thromboembolism after noncardiac surgery, direct oral anticoagulants may be preferred over low-molecular-weight heparin, according to a systematic review and meta-analysis.

LAA closure (Amplatzer Amulet, Abbott, or Watchman, Boston Scientific) or non-vitamin K antagonist oral anticoagulants in patients with AF.

In patients with cerebral venous thrombosis, direct oral anticoagulants were safer than warfarin without compromising efficacy, researchers reported at the International Stroke Conference.

Among patients with nonvalvular atrial fibrillation, those with frailty were less likely to receive an anticoagulant and, if anticoagulated, were more likely to receive warfarin than a direct oral anticoagulant, researchers reported.

This year, Transcatheter Cardiovascular Therapeutics was held as a hybrid meeting Nov. 4 to 6, with some participants attending in person in Orlando and others attending virtually.

Direct oral anticoagulant use appeared linked to high incidence of bleeding among patients with myeloproliferative neoplasms, according to study results presented at ASH Annual Meeting & Exposition.